Research:

Current Grant Support
The long-term goal is to create a powerful and efficient platform for developing small molecule inhibitors for panels of protein-protein interactions as an approach to modulating selected pathways and as a starting point for developing therapeutics. Role: Co-Investigator, 5%
Current Research Interests:
High Content Screening (HCS) was introduced by Cellomics (now Thermo-Fisher) in the mid-1990's as a method for high throughput cell biology. HCS sparked a revolution in imagebased cell analysis, going from a handful of measurements from a few hand-picked cells to multiplexed measurements on large populations of cells, providing statistically significant data on objectively chosen populations of cells. Meanwhile, genomics and proteomics profiling methods have resulted in inference maps of many, interconnected signaling pathways. In both cases, the principle focus has been on understanding the average activity of a population of cells. However, it has long been known that cellular activity is heterogeneous, and therefore the average activity, while certainly of interest, is not the whole story with regards to cellular function. The differential response of a minority of cells has important implications in cell biology, cancer, and drug discovery. An understanding of the differences at the level of the cellular pathways, will be important in understanding polypharmacology, and developing combination therapies to target the heterogeneity of the population, not just the majority.
To optimally address the heterogeneity at the cellular level, across a wide range of cellular function, requires the development of calibration methods for imaging cytometry, a method to enhance the multiplexing of cellular measurements, 'hyperplexing', and improved methods for the segmentation of subpopulations using the 'hyperplexed' data. A current research goal is to identify alternate signaling in subpopulations of cancer cells, and use that information to screen for combinations of drugs that are more effective in treating the whole population of cancer cells.
SERVICE:
2011-present: Member of the Faculty committee for the University of Pittsburgh Drug Discovery Institute 2010-present: Consultant for Cyprotex, Inc., a company that is providing in vitro safety assessment assays for drug discovery and development
